

Toronto Rehab - University Site ANTIBIOGRAM
All Inpatients
January 1, 2023 - December 31, 2023

Urine Isolates – % Susceptible

| | | ≥80% Susceptible ■ 70-79% Susceptible ■ ≤69% Susceptible ■ | | | Ampicillin | Amoxicillin-Clavulanic acid | Penicillin | Piperacillin-Tazobactam | Meropenem | Ertapenem | Cloxacillin | Cefazolin | Cephalexin | Ceftriaxone | Ceftazidime | Doxycycline | Ciprofloxacin | Trimethoprim-Sulfamethoxazole | Nitrofurantoin | Gentamicin | Tobramycin | Amikacin | Vancomycin | Linezolid |
|---------------------------------------------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-----------|------------|-----------------------------|------------|-------------------------|-----------|-----------|-------------|-----------|------------|-------------|-------------|-------------|---------------|-------------------------------|----------------|------------|------------|-----------|------------|-----------|
| # | % | | | | | | | | | | | | | | | | | | | | | | | |
| ALL BACTERIA | 270 | — | 25 | 72 | | | 84 | 76 | 60 | | | 13 | 1 | 61 | | 7 | 77 | 57 | 72 | | | | | |
| ALL GRAM-NEGATIVE BACTERIA | 203 | 100 | 5 | 68 | | | 83 | 100 | 79 | | | 17 | | 80 | 86 | 1 | 76 | 75 | 66 | 93 | 35 | 78 | | |
| <i>Escherichia coli</i> | 123 | 61 | 8 | 73 | | | 86 | 100 | 100 | | | 25 | | 90 | 90 | 0 | 72 | 77 | 95 | 91 | 14 | 86 | | |
| <i>Proteus mirabilis</i> | 27 | 13 | 0 | 100 | | | 96 | 100 | | | | | | 100 | 100 | 0 | 81 | 96 | 0 | 100 | | | | |
| <i>Klebsiella pneumoniae</i> | 23 | 11 | 0 | 82 | | | 83 | 100 | 100 | | | 0 | | 91 | 91 | 0 | 78 | 82 | 30 | 100 | 100 | 100 | | |
| <i>Pseudomonas aeruginosa</i> | 15 | 7 | | | | | 93 | 100 | | | | | | | 93 | | 80 | | | 80 | 100 | 93 | | |
| <i>Enterobacter cloacae</i> | 7 | 3 | 0 | 0 | | | 0 | 100 | 100 | | | 0 | 0 | 0 | 0 | | 86 | 86 | 43 | 100 | 100 | 100 | | |
| <i>Klebsiella oxytoca</i> | 3 | 1 | 0 | 100 | | | 100 | 100 | 100 | | | 100 | | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | | |
| <i>Citrobacter freundii</i> | 2 | 1 | 0 | 0 | | | 0 | 100 | 100 | | | 0 | 0 | 0 | 0 | | 100 | 100 | 100 | 100 | 100 | 100 | | |
| <i>Citrobacter koseri</i> | 2 | 1 | 0 | 0 | | | 0 | 100 | 100 | | | 0 | 0 | 0 | 0 | | 100 | 100 | 100 | 100 | 100 | 100 | | |
| <i>Morganella morganii</i> | 1 | 0 | 0 | 0 | | | 0 | 100 | 100 | | | 0 | 0 | 0 | 0 | | 100 | 0 | 0 | 100 | 100 | 100 | | |
| ALL GRAM-POSITIVE BACTERIA | 67 | 100 | 85 | 85 | | | 88 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | | 26 | 80 | 3 | 91 | | | | 100 | |
| <i>Enterococcus faecalis</i> , all isolates | 58 | 87 | 98 | 98 | | | 98 | | | | | | | | | 21 | 91 | | 98 | | | | 100 | |
| <i>Enterococcus faecium</i> , all isolates | 7 | 10 | 0 | 0 | | | 0 | | | | | | | | | 43 | 14 | | 29 | | | | 100 | 100 |
| <i>Staphylococcus aureus</i> , all isolates | 2 | 3 | | | | | 100 | 100 | 100 | 100 | 100 | 100 | | | | 100 | | 100 | 100 | | | | 100 | 100 |

General Notes:

- Statistical validity of estimates of percent susceptibility for organisms for which there are fewer than 30 isolates reported is limited. Please take this into consideration when interpreting the reported results.
- Some organisms for which there were only very small numbers have been excluded from this report; however the total number of "ALL BACTERIA", "ALL GRAM-NEGATIVE BACTERIA", and "ALL GRAM-POSITIVE BACTERIA" listed includes these organisms.
- Reported susceptibilities for "ALL BACTERIA", "ALL GRAM-NEGATIVE BACTERIA", and "ALL GRAM-POSITIVE BACTERIA" reflect estimates only based on the weighted average of susceptibilities for all organisms included on this report as well as those that have been excluded, with assumptions made for those drugs for which susceptibilities were not tested.
- Susceptibility to doxycycline was predicted based on tetracycline susceptibility testing results.

Toronto Rehab - University Site ANTIBIOGRAM
All Inpatients
January 1, 2023 - December 31, 2023

All Non-Urine Isolates – % Susceptible

| | # | % | Antibiotics | | | | | | | | | | | | | | | | | | | | |
|---------------------------------------------|----|-----|-------------|-----------------------------|------------|-------------------------|-----------|-----------|-------------|-----------|-------------|-------------|-------------|--------------|-------------|---------------|--------------|-------------------------------|------------|------------|----------|------------|-----------|
| | | | Ampicillin | Amoxicillin-Clavulanic acid | Penicillin | Piperacillin-Tazobactam | Meropenem | Ertapenem | Cloxacillin | Cefazolin | Ceftriaxone | Ceftazidime | Clindamycin | Erythromycin | Doxycycline | Ciprofloxacin | Moxifloxacin | Trimethoprim-Sulfamethoxazole | Gentamicin | Tobramycin | Amikacin | Vancomycin | Linezolid |
| ALL BACTERIA | 28 | – | 7 | 16 | | 84 | 89 | 68 | | 54 | 68 | | | | | | 70 | | | | | | |
| ALL GRAM-NEGATIVE BACTERIA | 10 | 100 | | 25 | | 75 | 100 | 40 | | 40 | 90 | | | | 85 | | 40 | 100 | 90 | 90 | | | |
| <i>Pseudomonas aeruginosa</i> | 5 | 50 | | | | 100 | 100 | | | | 100 | | | | 100 | | | 100 | 100 | 100 | | | |
| <i>Escherichia coli</i> | 3 | 30 | 0 | 50 | | 50 | 100 | 100 | | 0 | 100 | 100 | | | 50 | | 100 | 100 | 100 | 100 | | | |
| <i>Klebsiella pneumoniae</i> | 1 | 10 | 0 | 100 | | 100 | 100 | | | | 100 | 100 | | | 100 | | 100 | 100 | | | | | |
| <i>Citrobacter braakii</i> | 1 | 10 | 0 | 0 | | 0 | 100 | 100 | | 0 | 0 | 0 | | | 100 | | 0 | 100 | 100 | 100 | | | |
| ALL GRAM-POSITIVE BACTERIA | 18 | 100 | 11 | 11 | 6 | 89 | 83 | 83 | 78 | 83 | 83 | | | 59 | 59 | | | 88 | | | | 100 | |
| <i>Staphylococcus aureus</i> , all isolates | 15 | 83 | | | | 93 | 93 | 93 | 93 | 93 | | | | 66 | 66 | 93 | | 100 | | | | 100 | 100 |
| - methicillin-susceptible | 14 | 78 | | | | 100 | 100 | 100 | 100 | 100 | | | | 64 | 64 | 100 | | 100 | | | | 100 | 100 |
| - methicillin-resistant (MRSA) | 1 | 6 | | | | 0 | 0 | 0 | 0 | 0 | | | | 100 | 100 | 0 | | 100 | | | | 100 | 100 |
| Coagulase-negative staphylococci | 1 | 6 | | | | 0 | 0 | 0 | 0 | 0 | | | | 0 | 0 | 100 | | 0 | | | | 100 | 100 |
| Viridans group streptococci* | 1 | 6 | | | | 100 | | | | | | | | 100 | | | | | | | | 100 | |
| <i>Enterococcus faecalis</i> , all isolates | 1 | 6 | 100 | 100 | | 100 | | | | | | | | | | | | | | | | 100 | |

General Notes:

- Statistical validity of estimates of percent susceptibility for organisms for which there are fewer than 30 isolates reported is limited. Please take this into consideration when interpreting the reported results.
- Some organisms for which there were only very small numbers have been excluded from this report; however the total number of "ALL BACTERIA", "ALL GRAM-NEGATIVE BACTERIA", and "ALL GRAM-POSITIVE BACTERIA" listed includes these organisms.
- Reported susceptibilities for "ALL BACTERIA", "ALL GRAM-NEGATIVE BACTERIA", and "ALL GRAM-POSITIVE BACTERIA" reflect estimates only based on the weighted average of susceptibilities for all organisms included on this report as well as those that have been excluded, with assumptions made for those drugs for which susceptibilities were not tested.
- Susceptibility to doxycycline was predicted based on tetracycline susceptibility testing results.

Organism-Specific Notes:

- * Viridans group streptococci: Please note that only a small proportion of these isolates were tested for susceptibilities. Please take this into consideration when interpreting the reported results.